Table 3.
Results (per patient) of the base case (deterministic) and probabilistic analyses
| Base case (deterministic) analysis | |||||
|---|---|---|---|---|---|
| Treatment | Cost | QALY | Cost difference | QALY difference | ICER |
| EPFX | €10,046 | 0.638 | − €647 | 0.044 | EPFX dominates |
| Vancomycin | €10,693 | 0.594 | |||
| Probabilistic analysis | |||||
| Treatment | Cost | QALY | Cost difference | QALY difference | ICER |
| EPFX | €10,051 | 0.635 | − €646 | 0.043 | EPFX dominates |
| Vancomycin | €10,697 | 0.592 | |||
QALY quality-adjusted life-years, EPFX extended-pulsed fidaxomicin, ICER incremental cost-effectiveness ratio (cost per QALY gained with the most effective treatment)